Halozyme Therapeutics, Inc. announced that the Company is reiterating its financial guidance for 2024, which was initially provided on January 17, 2024. For the full year 2024, the Company expects: Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED®. Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
50.27 USD | +1.23% |
|
+0.70% | +36.01% |
Jun. 13 | Halozyme Therapeutics Insider Sold Shares Worth $1,006,300, According to a Recent SEC Filing | MT |
Jun. 11 | Halozyme Therapeutics May Seeks M&A | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.01% | 6.4B | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024